TScan Therapeutics completes IPO; Christoph Westphal resigns from board; charter amended

TScan Therapeutics, Inc.

Christoph Westphal, M.D., Ph.D. resigned from board effective after IPO pricing; no disagreement with management.
Amended charter authorizes 300M voting common shares, 10M non-voting common, 10M preferred shares.
Adopted classified board with staggered three-year terms; directors removable only for cause with 66 2/3% vote.
Bylaws revised to eliminate stockholder action by written consent and special meetings.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christoph Westphal

Director

TCRX · TScan Therapeutics, Inc.

Effective: 2021-07-15
Filed: July 20, 2021, 7:59 PM ET

On July 15, 2021, effective immediately after the pricing of the initial public offering (the “IPO”) of TScan Therapeutics, Inc. (the “Company”) Christoph Westphal, M.D., Ph.D., resigned from his position as a member of the Company’s board of directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christoph Westphal resigned as Director at TScan Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On July 15, 2021, effective immediately after the pricing of the initial public offering (the “IPO”) of TScan Therapeutics, Inc. (the “Company”) Christoph Westphal, M.D., Ph.D., resigned from his position as a member of the Company’s board of directors.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-219696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.